Skip to main content
Springer logoLink to Springer
. 2023 Feb 8;39(5):1225–1243. doi: 10.1007/s00381-023-05868-6

Surgical revascularizations for pediatric moyamoya: a systematic review, meta-analysis, and meta-regression analysis

Keng Siang Lee 1,2,3,4,5,✉,#, John J Y Zhang 6,#, Sanjay Bhate 2,7, Vijeya Ganesan 2,7, Dominic Thompson 1,2, Greg James 1,2, Adikarige Haritha Dulanka Silva 1,2
PMCID: PMC10167165  PMID: 36752913

Abstract

Introduction

There is no clear consensus regarding the technique of surgical revascularization for moyamoya disease and syndrome (MMD/MMS) in the pediatric population. Previous meta-analyses have attempted to address this gap in literature but with methodological limitations that affect the reliability of their pooled estimates. This meta-analysis aimed to report an accurate and transparent comparison between studies of indirect (IB), direct (DB), and combined bypasses (CB) in pediatric patients with MMD/MMS.

Methods

In accordance with PRISMA guidelines, systematic searches of Medline, Embase, and Cochrane Central were undertaken from database inception to 7 October 2022. Perioperative adverse events were the primary outcome measure. Secondary outcomes were rates of long-term revascularization, stroke recurrence, morbidity, and mortality.

Results

Thirty-seven studies reporting 2460 patients and 4432 hemispheres were included in the meta-analysis. The overall pooled mean age was 8.6 years (95% CI: 7.7; 9.5), and 45.0% were male. Pooled proportions of perioperative adverse events were similar between the DB/CB and IB groups except for wound complication which was higher in the former group (RR = 2.54 (95% CI: 1.82; 3.55)). Proportions of post-surgical Matsushima Grade A/B revascularization favored DB/CB over IB (RR = 1.12 (95% CI 1.02; 1.24)). There was no significant difference in stroke recurrence, morbidity, and mortality. After meta-regression analysis, year of publication and age were significant predictors of outcomes.

Conclusions

IB, DB/CB are relatively effective and safe revascularization options for pediatric MMD/MMS. Low-quality GRADE evidence suggests that DB/CB was associated with better long-term angiographic revascularization outcomes when compared with IB, although this did not translate to long-term stroke and mortality benefits.

Supplementary Information

The online version contains supplementary material available at 10.1007/s00381-023-05868-6.

Keywords: Neurosurgery, Pediatric, Moyamoya disease, Moyamoya syndrome, Bypass, Revascularization

Introduction

Moyamoya disease (MMD) or syndrome (MMS) refers to an abnormal progressive steno-occlusive disorder at the distal internal carotid artery (ICA) [1]. Patients are at high risk for transient ischemic stroke (TIA) or stroke. It is asserted that surgical revascularization provides better outcomes for these patients than medical treatment alone. In pediatric patients, the goal of surgery is to augment cerebral blood flow and reduce the risk of ischemic events [2].

Revascularization techniques can be direct, indirect, or combined. Direct bypass (DB) is accomplished by anastomosing extracranial vessels to intracranial vessels (EC-IC bypass), most often the superficial temporal artery (STA) to the middle cerebral artery (MCA) (STA-MCA bypass) [3, 4]. Indirect bypass (IB) has many variations but is generally accomplished by incorporating well-vascularized tissue usually from external carotid artery sources onto the surface of the brain to promote angiogenesis and neovascularization, rather than by direct anastomosis [59]. Unlike DB, IB begins to alter the cerebral blood flow only after angiogenesis has taken place, the timescale for which is unpredictable [3]. A combined bypass (CB) utilizes both techniques simultaneously to maximize the effect of short-term and long-term revascularization [3].

There is currently no definite consensus regarding the technique of surgical revascularization in pediatric MMD/MMS [1, 2]. Existing meta-analyses have elegantly attempted to address this controversy in pediatric patients [10, 11]. However, in these studies, repeated patient populations from the same institutions within overlapping time intervals were included [10, 11]. This methodological flaw overstates sample size and number of events, leading to an artificially exaggerated precision in their pooled estimate [12]. In addition, several included primary studies in these meta-analyses had not distinguished outcomes based on the type of bypass nor specifically for children, and hence it was unclear how these meta-analyses were able to distinguish between the techniques or population. This meta-analysis aimed to mitigate against previous methodological limitations and report an accurate and transparent comparison between studies of IB, DB, and CB in pediatric patients with MMD/MMS.

Methods

This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [13]. The protocol was registered on the PROSPERO international prospective register (CRD42022365524).

Outcomes

The primary outcome included any reported perioperative adverse events within 30 days after bypass surgery. This included wound complications, seizures, cerebrospinal fluid (CSF) leak extra-axial hemorrhage, TIA, stroke, and death.

Secondary outcomes included modified Rankin score (mRS), long-term stroke, mortality risk, and degree of angiographic revascularization at last follow-up. The degree of revascularization was graded according to Matsushima’s classification of the proportion of arterial territory (Grade A > 2/3, Grade B = 1/3 to 2/3, Grade C < 1/3) [3].

When angiographic assessment in the primary studies was graded according to a 3-grade classification (poor, moderate, or good), or 4-grade classification (none, poor, medium, or extensive) [14], we classified “good” and “extensive” as Grade A, “moderate” and “medium” as Grade B, and “poor” or “none” as Grades C.

Search strategy

Searches of three electronic databases were undertaken: Ovid Medline, Ovid Embase, and Cochrane Central Register of Controlled Trials (CENTRAL). Searches were performed in each database from its inception until 7 October 2022. The full search strategy is presented in Supplementary Table 1.

Eligibility criteria

Articles were selected for inclusion if they were a primary interventional or observational study evaluating the effectiveness and safety of revascularization surgeries in pediatric MMD/MMS. The review included studies on exclusively pediatric patients (< 18 years). Studies that had evaluated both pediatric and adult MMD/MMS but reported outcomes specific to the pediatric population were included. Studies that had evaluated various revascularization techniques but reported outcomes specific for the particular technique were included.

The review excluded narrative and systematic reviews, editorials, commentaries, opinion papers, letters, education papers, conference abstracts, protocols, reports, theses, or book chapters as they were unlikely to contain sufficient detail about the effectiveness and safety of both treatments.

Study selection

All titles and abstracts were screened against the pre-defined eligibility criteria developed independently by two reviewers (KSL and JJYZ). A full list of inclusion and exclusion criteria of studies is stated in Supplementary Table 2. Disagreements were resolved by discussion, and where agreement could not be reached, the senior reviewer assisted with decision-making (AHDS). Agreement among the reviewers was evaluated using Cohen’s kappa [15].

The institutions and data collection period were scrutinized to avoid multiple counting. In the event of multiple publications analyzing the same cohort of patients/hemispheres, the publication that reported the largest patient data with the most relevant outcomes was used for evaluation.

Data extraction

A pro forma was developed and piloted to extract data on the following variables to ensure standardization and consistency in this process: (1) study details; (2) study design; (3) participant demographics; (4) country, institution, and data collection period; (5) selection criteria; (6) treatment and control; (7) indication for treatment; and (8) results.

Risk of bias assessment

The quality of included studies was assessed using the Joanna Briggs Institute (JBI) checklist for cohort studies and case series [16]. KSL and JJYZ assessed the quality of all included studies and discussed discrepancies until consensus was reached.

Statistical analysis

Meta-analyses of primary end points were performed assuming the random effects model to account for heterogeneity within and between individual studies [16].

We analyzed both DB and CB as a single cohort compared with IB. The rationale is that in CB, patients undergo a direct and an indirect component of the revascularization in the same setting. The direct component would afford an immediate increase in cerebral perfusion, while the indirect collateralization would take months to a year to form [3]. As reported denominators were heterogenous, analyses by both patients and hemispheres were performed whenever possible. To obtain risk ratios (RRs) from reported binary outcomes between DB/CB and IB, a pairwise meta-analysis was conducted using the Mantel–Haenszel method, using the Paule-Mandel estimator. Overall pooled proportions were computed using the generalized linear mix model (GLMM) [16]. Knapp-Hartung adjustments were used to calculate the 95% confidence intervals (CIs) around the pooled effect to reduce the risk of a Type 1 error.

For the pooling of means of numerical variables, we computed missing means and standard deviations (SDs) from medians, ranges, and interquartile ranges (IQRs) using the methods proposed by Hozo et al. and Wan et al. [17, 18].

The I2 statistic was used to present inter-study heterogeneity, where I2 ≤ 30%, between 30 and 50%, between 50 and 75%, and ≥ 75% were considered to indicate low, moderate, substantial, and considerable heterogeneity, respectively [16]. P values for the I2 statistic were derived from the chi-squared distribution of Cochran’s Q test.

Summary-level meta-regression was performed using the mixed-effects model after computation of the SD of Freeman-Tukey double arcsine transformed proportions, to identify predictors of perioperative TIA, stroke, long-term revascularization, stroke, and mortality. Predictors were year of publication, age, presence of MMS, presence of sickle cell disease (SCD), neurofibromatosis (NF1), and Down syndrome, in accordance with the literature [5, 7, 19, 20]. Summary-level meta-regression was additionally performed using a mixed-effect meta-analysis model by the GLMM method, as a sensitivity analysis to examine the robustness of the former approach.

The publication bias of studies was assessed visually using funnel plots and quantitatively using Egger’s regression test [16]. The GRADE approach was used to evaluate the quality of evidence for each outcome.

All statistical analyses were performed using R software version 4.2.1 (R Foundation for Statistical Computing, 2022), with the package meta. P values less than 0.05 were considered statistically significant.

Results

Study selection and characteristics

As expected, a substantial number of studies were excluded because they had reported data from the same cohort of patients/hemispheres across overlapping time periods. These were commonly from large high-volume institutions such as Beijing Tiantan Hospital [2125], Boston Children’s Hospital [59, 20, 2630], and Seoul National University Children’s Hospital [3134]. Consequently, only one publication that reported the largest patient data with the most relevant outcomes was included in our analysis.

Thirty-seven studies met the eligibility criteria for inclusion in our systematic review and meta-analysis (Fig. 1) [24, 19, 3567]. The reliability of the study selection was substantial at both the title and abstract (Cohen’s κ = 0.86) and the full-text review stages (Cohen’s κ = 1.00) [15].

Fig. 1.

Fig. 1

PRISMA flow diagram for studies included and excluded

All included studies were retrospective observational studies—eight cohort studies and 29 case series. A total of 37 studies reporting 2460 pediatric patients were included. Only 36 studies had reported the number of hemispheres, and the total hemisphere count was 4432. Thirty-two studies reported outcomes of IB. Of these, 31 studies reported the number of hemispheres in the IB group (3524) and all 34 reported the number of patients (2227). Seventeen studies reported outcomes of DB/CB. All 17 studies reported the number of hemispheres in the DB/CB group (905) whilst only 10 reported the number of patients (358). Eleven studies compared outcomes between the IB and DB/CB groups (Table 1).

Table 1.

Summary of included studies

First author and year Country Study design Institution Study period Total hemispheres/surgeries, n Total patients, n Type of revascularization Etiology, n Imputed mean age at surgery (SD), year* Male, n (%)
Alamri et al. (2019) [35] UK Case series King’s College Hospital 2007 to 2015 9 8 IB–EDAS 8 MMMS, 8 SCD 12.7 (2.6) 4 (50.0)
Araki et al. (2022) [36] Japan Cohort study Nagoya University Graduate School of Medicine 2005 to 2021 39 21 IB–EDMS, DB–STAMCA 21 MMD 3.6 (1.1) NR
Bao et al. (2015) [37] China Case series People's Liberation Army (PLA) Hospital 2002 to 2010 512 288 IB–EDAS 288 MMD 9.9 (4.9) 146 (50.7)
Blauwblomme et al. (2017) [38] France Case series Necker Hospital 1999 to 2015 108 64 IB–MBH

32 MMMS,

7 SCD, 7 DS, 8 NF1

9.1 (4.1) 33 (51.6)
Chen et al. (2018) [39] China Case series The Third Affiliated Hospital 2002 to 2015 18 10 IB–Pial synangiosis MMD 8.5(1.9) 2 (20.0)
Czabanka et al. (2009) [40] Germany Case series Charité-Universitätsmedizin Berlin NR 20 10 IB–EMS, DB–STAMCA MMD 8.4 (6.4) 4 (40.0)
Darwish et al. (2005) [41] Australia Case series Royal Alexandra Hospital for Children 1982 to 2004 21 13 IB–EDAS, EMS, DB–STAMCA 4 MMMS, 3 NF1, 1 cranial radiation 6.1 (3.9) 5 (38.5)
De Oliveira et al. (2009) [42] Mexico Case series Ribeirao Preto Medical School 2003 to 2008 14 7 IB–MBH 3 MMS, 3DS 8.4 (3.7) 2 (28.6)
Deng et al. (2021) [43] China Cohort study Beijing Tiantan Hospital 2010 to 2019 533 336 IB–EDAS, MBH, DB–STAMCA MMD 9.6 (3.7) NR
Funaki et al. (2014) [44] Japan Case series Kyoto University Graduate School of Medicine 1978 to 2003 114 58 DB–STAMCA MMD 6.4 (4.3) 24 (41.4)
Furtado et al. (2021) [45] India Case series MS Ramaiah Medical College and Hospital 2006 to 2019 50 28 IB–EDAS MMD NR NR
Gadgil et al. (2018) [46] USA Case series Texas Children’s Hospital 1997 to 2016 169 102 IB–EDAS, dural inversion 60 MMS, 43 SCD, 5 DS, 1 NF1, 8 cranial radiation, 1 ACTA2 10.9 (6.8) 46 (45.1)
Goren et al. (2021) [47] Israel Case series Sheba Medical Center Hospital 2000 to 2019 49 27 IB–EDAS, dural inversion 5 MMS, 3 DS, 1 NF1, 1 AS 7.0 (4.7) 16 (59.3)
Griessenauer et al. (2015) [48] USA Case series University of Alabama at Birmingham 2007 to 2014 21 14 IB–EDAS, EMAS 14 MMMS, 14 SCD 15.3 (5.3) 5 (35.7)
Guzman et al. (2009) [49] USA Cohort study Stanford University Medical Center 1991 to 2008 168 96 IB–EDAS, EDMS, DB–STAMCA 16 MMS, 3 DS, 5 NF1, 1 AS 9.8 (4.9) NR
Ha et al. (2019) [50] Korea Case series Seoul National University Children’s Hospital 1988 to 2012 1283 629 IB–EDAS, MBH MMMD 7.7 (4.7) 303 (48.2)
Hall et al. (2016) [51] USA Case series Multi-center – Riley Hospital for Children at Indiana University Health and St. Louis Children’s Hospital/Washington University School of Medicine 2000 to 2014 20 12 IB–EDAS, MBH 12 MMS, 12 SCD NR 8 (66.7)
Ishikawa et al. (1997) [52] Japan Cohort study Hokkaido University School of Medicine, Sapporo, Japan 1988 to 1995 64 34 IB–EDAMS, EDAS, DB–STAMCA MMD 7.6 (3.6) 15 (44.1)
Isono et al. (2002) [53] Japan Case series Oita Medical University 1983 22 11 IB–EDAMS, EDAS MMD 6.3 (2.9) NR
Karasawa et al. (1992) [54] Japan Case series Osaka Neurological Institute 1974 to 1991 196 104 IB–EMS MMD NR NR
Kennedy et al. (2014) [19] USA Case series Columbia University Medical Center/Morgan Stanley Children’s Hospital of New York 1996 to 2012 27 17 IB–pial synangiosis 17 MMS, 17 SCD NR 8 (47.1)
Kim et al. (2007) [55] Korea Cohort study The Catholic University of Korea College of Medicine, Uijeongbu St. Mary’s Hospital NR 36 24 IB–EDAMS, EDAS, STAMCA MMD NR 12 (50.0)
King et al. (2010) [56] Canada Case series Hospital for Sick Children 1996 to 2008 18 12 IB–pial synangiosis, MBH 12 NR 13
Kuroda et al. (2010) [57] Japan Case series Hokkaido University Graduate School of Medicine 1998 to 2009 47 28 IB–EDAMS, DB–STAMCA MMD 9.8 (3.8) 7 (25.0))
Matsushima et al. (1998) [3] Japan Case series Kyushu University Graduate School of Medical Sciences 1983 to 1986 72 50 IB–EDAS, EMAS, EMS, DB–STAMCA MMD NR NR
Mirone et al. (2019) [58] Italy Case series Santobono- Pausilipon Children’s Hospital 2007 to 2016 14 10 IB–MBH 6 MMS, 3 NF1, 2 cranial radiation NR NR
Morshed et al. (2020) [4] USA Cohort study University of California San Francisco 2006 to 2018 49 26 IB–EDAMS, EDAS, EMS, DB–STAMCA 11 MMD, 1 DS, 4 NF1, 1 cranial radiation, 2 ACTA2 8.5 (4.8) NR
Ng et al. (2012) [59] UK Case series Great Ormond Street Hospital 1996 to 2010 134 73 IB–EDMS, EDAS, pial synangiosis, DB–STAMCA 27 MMS, 13 SCD, 7 DS, 4 NF1, 10 congenital cardiac abnorality,, 2 renal artery stenosis 8.4 (4.9) 31 (42.5)
Ogiwara and Morota (2012) [60] Japan Case series National Center for Child Health and Development, Tokyo 2003 to 2010 22 12 IB–EDAS, EGS MMD 6.4 (2.2) 7 (58.3)
Ong et al. (2020) [61] Singapore Case series Multi-center – KK Women’s and Children’s Hospital and the National University Hospital of Singapore 2002 to 2019 23 15 IB–EDAS, EMAS, pial synangiosis, DB–STAMCA MMD 9.4 (4.7) 5 (33.3)
Rashad et al. (2016) [62] Japan Case series Tohoku University Graduate School of Medicine 2004 to 2015 39 23 IB–EDMS, DB–STAMCA 1 MMMS, 1 NF1 9.4 (4.0) NR
Sadashiva et al. (2016) [63] India Cohort study National Institute of Mental Health and Neurosciences 2006 to 2014 85 54 IB–E DAMS, DB–STAMCA MMMD 9.0 (4.7) 25 (46.3)
Sakamoto et al. (1997) [64] Japan Case series Oaska City General Hospital 19 10 IB–EMS, DB–STAMCA MMD NR 0 (0.0)
Scott et al. (2004) [2] USA Case series Boston Children’s Hospital 1985 to 2001 271 143 IB–Pial synangiosis 77 MMS, 3 SCD, 10 DS, 16 NF1, 15 cranial radiation, 7 congenital cardiac abnorality, 4renal artery stenosis 7.1 (6.0) 54 (37.8)
Shen et al. (2017) [65] China Case series Fudan 2011 to 2014 134 77 IB–EDMS 6.5 38
Winstead et al. (2017) [66] USA Case series Children’s Hospital and Research Center Oakland 2007 NR 7 IB–EDAS 7 MMS, 7 SCD NR 2 (28.6)
Yang et al. (2017) [67] USA Case series Johns Hopkins University School of Medicine 1990 to 2015 12 7 IB–EDAMS, EDAS, pial synangiosis 7 MMS, 7 SCD 6.9 (4.0) 4 (57.1)

AS alagille syndrome, DB direct bypass, DS Down syndrome, EDAS encephaloduroateriosynangiosis, EDAMS encephaloduroarteriomyosynangiosis, EDMS encephaloduromyosynangiosis, EGS encephalogaleosynangiosis, EMAS encephalomyoarteriosynangiosis, EMS encephalomyosynangiosis, IB indirect bypass, MBH multiple burr holes, MMD moyamoya disease, MMS moyamoya syndrome, NF1 neurofibromatosis 1, NR not reported, SCD sickle cell disease, STA-MCA superficial temporal artery to middle cerebral artery bypass, UK United Kingdom, USA United States

*Unless otherwise stated. For pooling of means of numerical variables, we computed missing means and standard deviations (SDs) from medians, ranges (minimum to maximum), and interquartile ranges (IQRs) using the methods proposed by Hozo et al. and Wan et al.

Risk of bias assessment using the JBI checklist for cohort studies and case series are reported in Supplementary Tables S3 and S4.

Baseline characteristics of patients

The gender of the patients was reported in 25 studies in a total of 1731 patients—45.0% male and 55.0% female. The mean and SD of their age were reported or imputable in 29 studies in a total of 2204 patients. Overall pooled mean age was 8.6 years (95% CI: 7.7; 9.5, I2 = 95.3% [p < 0.001]). In total, 308 patients had MMS. The pooled prevalence of MMS within the included population was 21.7% (95% CI: 1.1–86.9%, I2 = 54.2 [p < 0.001]). The number of patients with associated SCD, NF1, Down syndrome, cranial radiation, congenital cardiac abnormality, renal artery stenosis, ACTA2 mutation, and Alagille syndrome were 131 (42.5%), 47 (15.3%), 40 (13.0%), 24 (7.8%), 18 (5.8%), 6 (1.9%), 3 (1.0%), and 3 (1.0%), respectively.

Perioperative adverse events

Table 2 presents a detailed summary of the pooled outcomes in each group and Table 3 presents a direct comparison of outcomes between the two groups. Table 4 summarizes the predictors of these outcomes identified on meta-regression.

Table 2.

Pooled outcomes of included patients/hemispheres between the two groups (indirect bypass and direct/combined bypass)

Outcomes Indirect bypass Direct and combined bypass
No. of studies reporting variable No. of patients/ hemispheres analyzed Pooled proportion [95% confidence interval] I2 (%) P value of I2 (from χ2 test) Quality of Evidence (GRADE) No. of studies reporting variable No. of patients/ hemispheres analyzed Pooled proportion [95% confidence interval] I2 (%) P value of I2 (from χ2 test) Quality of Evidence (GRADE)
Perioperative adverse events
Perioperative seizures (hemispheres) 8 2473 0.84 [0.16; 4.26] 79.0  < 0.001 Low 2 140 0.00 [0.00; 1.00] 0.0 1.000 Low
Perioperative seizures (patients) 7 1060 1.32 [0.17; 9.38] 77.1  < 0.001 Low NA NA NA NA NA NA
Perioperative subdural hygroma (hemispheres) 3 44 4.55 [0.21; 51.74] 0.0 0.993 Low NA NA NA NA NA NA
Perioperative subdural hygroma (patients) 3 32 6.25 [0.29; 60.69] 0.0 0.996 Low NA NA NA NA NA NA
Perioperative extra-axial hemorrhage (hemispheres) 8 2592 1.53 [0.62; 3.75] 0.0 0.544 Low NA NA NA NA NA NA
Perioperative extra-axial hemorrhage (patients) 7 1126 4.09 [2.86; 5.80] 5.2 0.387 Low NA NA NA NA NA NA
Perioperative intracerebral hemorrhage (hemispheres) 4 1326 0.36 [0.01; 11.14] 62.3 0.047 Low NA NA NA NA NA NA
Perioperative intracerebral hemorrhage (patients) 4 656 0.46 [0.07; 2.82] 57.4 0.070 Low NA NA NA NA NA NA
Perioperative wound complication (hemispheres) 8 810 1.18 [0.31; 4.46] 54.1 0.033 Low 4 177 2.26 [0.46; 10.36] 0.0 0.584 Low
Perioperative wound complication (patients) 6 210 3.01 [0.61; 13.46] 41.0 0.132 Low 2 33 3.03 [0.00; 99.99] 0.0 1.000 Low
Perioperative CSF leak (hemispheres) 8 1245 1.00 [0.34; 2.89] 30.6 0.184 Low 2 125 1.60 [0.00; 99.29] 0.0 0.573 Low
Perioperative CSF leak (patients) 7 459 1.72 [0.39; 7.30] 37.7 0.141 Low NA NA NA NA NA NA
Perioperative hydrocephalus requiring shunt (hemispheres) 2 178 0.56 [0.00; 99.95] 0.0 1.000 Low NA NA NA NA NA NA
Perioperative hydrocephalus requiring shunt (patients) 2 110 0.91 [0.00; 99.97] 0.0 1.000 Low NA NA NA NA NA NA
Perioperative TIA (hemispheres) 16 1782 2.62 [1.14; 5.91] 67.8  < 0.001 Low 6 328 7.61 [2.20; 23.15] 78.8  < 0.001 Low
Perioperative TIA (patients) 16 753 4.52 [1.95; 10.09] 59.1  < 0.001 Low 3 106 9.74 [0.35; 76.75] 82.0 0.004 Low
Perioperative stroke (hemispheres) 24 3394 3.19 [1.91; 5.30] 54.8  < 0.001 Low 9 492 4.55 [2.04; 9.84] 53.1 0.030 Low
Perioperative stroke (patients) 20 1506 5.94 [3.74; 9.29] 26.1 0.138 Low 3 89 5.62 [0.81; 30.14] 0.0 0.905 Low
Perioperative death (patients) 20 1224 0.00 [0.00; 1.00] 0.0 1.000 Low 6 179 0.56 [0.04; 6.89] 0.0 1.000 Low
Outcomes at last follow-up
Revascularization Matsushima Grade A (hemispheres) 14 822 56.70 [44.32; 68.29] 83.4  < 0.001 Low 5 284 44.40 [5.75; 91.27] 0.0 0.662 Low
Revascularization Matsushima Grades A and B (hemispheres) 14 822 85.61 [78.84; 90.48] 54.3 0.008 Low 5 284 95.42 [17.79; 99.95] 76.8 0.002 Low
Stroke recurrence at last follow-up (hemispheres) 9 1599 2.34 [0.88; 6.06] 64.8 0.004 Low 7 411 2.38 [0.39; 13.28] 0.0 0.996 Low
Stroke recurrence at last follow-up (patients) 16 1416 5.24 [2.97; 9.08] 54.6 0.005 Low 6 233 5.87 [1.41; 21.41] 0.0 0.890 Low
mRS0-1 at last follow-up (patients) 8 604 80.38 [68.67; 88.45] 81.0  < 0.001 Low 4 144 87.44 [39.85; 98.65] 0.0 0.734 Low
mRS2-3 at last follow-up (patients) 5 481 25.28 [3.97; 73.49] 39.8 0.156 Low NA NA NA NA NA NA
Mortality at last follow-up (patients) 18 1454 0.30 [0.08; 1.17] 0.0 1.000 Low 5 210 0.48 [0.03; 7.18] 0.0 1.000 Low

NA not applicable as fewer than 2 studies reported the outcome by hemisphere/patients

*When the pooled proportions (GLMM method) provided 95% CI of zero to one or nearly one, we advise to interpret with caution as the estimate is likely not reliable

Table 3.

Direct comparison of outcomes between the two groups (indirect bypass and direct/combined bypass with indirect bypass as control)

Outcomes No. of studies reporting variable No. of patients/hemispheres analyzed Pooled effect size [95% confidence interval] I2 (%) P value ofI2 (fromχ2 test) Quality of Evidence (GRADE)
Perioperative wound complications (hemispheres) 2 582 RR 2.54 [1.82; 3.55] 0.0 0.978 Low
Perioperative seizures (hemispheres) 2 605 RR 0.25 [0.00; 2022.04] 0.0 0.514
Perioperative TIA (hemispheres) 5 935 RR 0.64 [0.38; 1.10] 0.0 0.786 Low
Perioperative stroke (hemispheres) 6 1056 RR 1.04 [0.41; 2.65 18.9 0.290 Low
Total perioperative complications (hemispheres) 7 1056 RR 1.01 [0.86; 1.17] 1.2 0.415 Low
Perioperative death (hemispheres) 2 1162 RR 0.72 [0.00; 5682.31] 0.0 0.538 Low
Perioperative death (patients) 2 159 RR 0.96 [0.04; 22.76] NA NA Low
Revascularization Matsushima Grade A (hemispheres) 3 144 RR 1.56 [0.99; 2.46] 0.0 0.707 Low
Revascularization Matsushima Grades A and B (hemispheres) 3 144 RR 1.12 [1.02; 1.24] 0.0 0.878 Low

Table 4.

Predictors of outcome identified on meta-regression

Outcome No. of studies reporting outcome and risk factor Total no. of patients/hemispheres analyzed Predictor P value
Indirect
  Perioperative stroke

24

24

24

24

24

24

3394

3394

3394

3394

3394

3394

Publication year

Age

Proportion of MMS

Proportion of SCD

Proportion of NF1

Proportion of DS

0.128

0.048

0.153

0.221

0.749

0.151

  Perioperative TIA

16

16

16

16

16

16

753

753

753

753

753

753

Publication year

Age

Proportion of MMS

Proportion of SCD

Proportion of NF1

Proportion of DS

0.795

0.141

0.867

0.307

0.162

0.133

  Revascularisation (Matsushima grades A and B)

14

14

14

14

14

14

822

822

822

822

822

822

Publication year

Age

Proportion of MMS

Proportion of SCD

Proportion of NF1

Proportion of DS

0.464

0.168

0.934

0.873

0.996

0.342

  Stroke recurrence

16

16

16

16

16

16

1416

1416

1416

1416

1416

1416

Publication year

Age

Proportion of MMS

Proportion of SCD

Proportion of NF1

Proportion of DS

0.770

0.206

0.608

0.274

0.818

0.751

  Mortality

18

18

18

18

18

18

1454

1454

1454

1454

1454

1454

Publication year

Age

Proportion of MMS

Proportion of SCD

Proportion of NF1

Proportion of DS

0.044

0.425

0.071

0.334

0.496

0.372

Direct/combined
  Perioperative stroke

9

8

4

NA

4

NA

492

438

383

NA

383

NA

Publication year

Age

Proportion of MMS

Proportion of SCD

Proportion of NF1

Proportion of DS

0.837

0.005

0.558

NA

0.357

NA

  Perioperative TIA

6

6

NA

NA

NA

NA

328

328

NA

NA

NA

NA

Publication year

Age

Proportion of MMS

Proportion of SCD

Proportion of NF1

Proportion of DS

0.910

 < 0.001

NA

NA

NA

NA

  Revascularisation (Matsushima grades A and B)

5

NA

NA

NA

NA

NA

284

NA

NA

NA

NA

NA

Publication year

Age

Proportion of MMS

Proportion of SCD

Proportion of NF1

Proportion of DS

0.057

NA

NA

NA

NA

NA

  Stroke recurrence

7

5

NA

NA

NA

NA

411

196

NA

NA

NA

NA

Publication year

Age

Proportion of MMS

Proportion of SCD

Proportion of NF1

Proportion of DS

0.291 0.010

NA

NA

NA

NA

  Mortality

5

NA

NA

NA

NA

NA

210

NA

NA

NA

NA

NA

Publication year

Age

Proportion of MMS

Proportion of SCD

Proportion of NF1

Proportion of DS

0.566

NA

NA

NA

NA

NA

NA not applicable as there were too few studies for an accurate meta-regression

Overall pooled rates of perioperative seizures by hemispheres in the IB and DB/CB groups were 0.84% (95% CI: 0.16; 4.26, I2 = 79.0 [p < 0.001]) and 0.00% (95% CI: 0.00; 1.00, I2 = 0.0 [p = 1.000]) respectively. Two studies of 582 hemispheres directly compared rates of perioperative seizures between the two groups. Perioperative seizure rate was comparable between IB and DB/CB (RR = 0.25 (95% CI: 0.00; 2022.03), I2 = 0.0 [p = 0.514]). Overall pooled rates of perioperative wound complications by hemispheres in the IB and DB/CB groups were 1.18% (95% CI: 0.31; 4.46, I2 = 54.1 [p = 0.033]) and 2.26% (95% CI: 0.46; 10.36, I2 = 0.0 [p = 0.584]), respectively. Overall pooled rates of perioperative wound complications by patients in the IB and DB/CB groups were 3.01% (95% CI: 0.61; 13.46, I2 = 41.0 [p = 0.132]) and 3.03% (95% CI: 0.00; 99.99, I2 = 0.0 [p = 1.000]), respectively. Two studies of 582 hemispheres directly compared rates of perioperative wound complications between the two groups. Perioperative wound complications rate was significantly higher in the DB/CB group (RR = 2.54 (95% CI: 1.82; 3.55), I2 = 0.0 [p = 0978]) (Fig. 2a). Overall pooled rates of perioperative CSF leak by hemispheres in the IB and DB/CB groups were 1.00% (95% CI: 0.34; 2.89, I2 = 30.6 [p = 0.184]) and 1.6% (95% CI: 0.00; 99.29, I2 = 0.0 [p = 0.573]), respectively. No direct comparison was available for rates of perioperative CSF leaks.

Fig. 2.

Fig. 2

Forest plot comparing rates of a perioperative wound complication, b Matsushima grade A, and c Matsushima grade A/B between DB/CB versus IB

Overall pooled rates of perioperative TIA by hemispheres in the IB and DB/CB groups were 2.62% (95% CI: 1.14; 5.91, I2 = 67.8 [p < 0.001]) and 7.61% (95% CI: 2.20; 23.15, I2 = 78.8 [p < 0.001]), respectively. Pooled rates of perioperative TIA by patients in the IB and DB/CB groups were 4.52% (95% CI: 1.95; 10.09, I2 = 59.1 [p < 0.001]) and 9.74% (95% CI: 0.35; 76.75, I2 = 82.0 [p = 0.004]), respectively. Five studies of 935 hemispheres directly compared rates of perioperative TIA. Perioperative TIA rate was comparable between IB and DB/CB (RR = 0.64 (95% CI: 0.38; 1.10), I2 = 0.0 [p = 0.786]). Pooled rates of perioperative stroke by hemispheres in the IB and DB/CB groups were 3.19% (95% CI: 1.915.30, I2 = 54.8 [p < 0.001]) and 4.55% (95% CI: 2.04; 9.84, I2 = 53.1 [p = 0.030]), respectively. Two studies directly compared rates of perioperative stroke by hemispheres and patients and showed comparability (RR = 0.25 (95% CI: 0.00; 2022.04), I2 = 0.0 [p = 0.514]) and (RR = 0.72 (95% CI: 0.00; 5682.31), I2 = 0.0 [p = 0.538]), respectively. On meta-regression, age significantly predicted rates of perioperative stroke (p = 0.048) in the IB group (Fig. 3a). Further meta-regression demonstrated age further significantly predicted rates of perioperative TIA (p = 0.005) and perioperative stroke (p < 0.001) in the DC/CB group (Fig. 3b and c, respectively).

Fig. 3.

Fig. 3

Bubble plot for meta-regression of transformed proportion of a perioperative stroke against age in each IB study, b perioperative stroke against age in each DB/CB study, c perioperative TIA against age in each DB/CB study, d mortality against year of publication in each IB study, and e transformed proportion of long-term stroke recurrence against age in each DB/CB study

Pooled rates of perioperative death in the IB and DB/CB groups were 0.00% (95%CI: 0.00; 1.00, I2 = 0.0 [p = 1.000]) and 0.56% (95%CI: 0.00; 6.89, I2 = 0.0 [p = 1.000]), respectively. Direct comparison between the groups showed comparability (RR = 0.96 (95% CI: 0.04; 22.76), I2 = NA [p = NA]).

Revascularization

Angiographical follow-up duration was reported in 9 studies comprising 1150 hemispheres and pooled duration was 4.3 years (95% CI: 2.2; 6.4, I2 = 99.5 [p < 0.001]).

In the IB group, overall pooled rates of hemispheres with Grade A and Grade A/B revascularization were 56.70% (95% CI: 44.32; 68.29, I2 = 83.4 [p < 0.001]) and 85.61% (95% CI: 78.84; 90.48, I2 = 54.3 [p = 0.008]). In DB/CB group, overall pooled rates of hemispheres with Grade A and Grade A/B revascularization were 44.44% (95% CI: 5.75; 91.27, I2 = 0.0 [p = 0.662]) and 95.42% (95% CI: 17.79; 99.95, I2 = 76.8 [p = 0.002]). Three studies of 144 hemispheres directly compared proportions of Grade A and Grade A/B revascularization. No significant difference in the proportion of Grade A was identified (RR = 1.56 (95% CI 0.99; 2.46), I2 = 0.0 [p = 0.707]), but proportions of Grade A/B favored DB/CB over IB (RR = 1.12 (95% CI 1.02; 1.24), I2 = 0.0 [p = 0.878]) (Fig. 2b and c).

Stroke recurrence, dependence, and mortality at last follow up

Clinical follow-up duration was reported in 33 studies with a total of 1992 patients and pooled duration was 6.5 years (95% CI: 4.4; 8.6, I2 = 99.0 [p < 0.001]).

Overall pooled rates of stroke recurrence by hemispheres at last follow-up in the IB and DB/CB groups were 2.34% (95% CI: 0.88; 6.06, I2 = 64.8 [p = 0.004]) and 2.38% (95% CI: 0.39; 13.28, I2 = 0.0 [p = 0.996]), respectively. Overall pooled rates of stroke recurrence by patients at last follow-up in the IB and DB/CB groups were 5.24% (95% CI: 2.97; 9.08, I2 = 51.6 [p = 0.005]) and 5.87% (95% CI: 1.41; 21.41, I2 = 0.0 [p = 0.890]), respectively. On meta-regression, age (p = 0.010) significantly predicted stroke recurrence in the DC/CB group (Fig. 3e).

Overall pooled rates of patients with mRS scores of 0 and 1 at last follow-up in the IB and DB/CB groups were 80.38% (95% CI: 68.67; 88.45, I2 = 81.0 [p < 0.001]) and 87.44% (95% CI: 39.85; 98.65, I2 = 0.0 [p = 0.734]), respectively. Overall pooled rates of mortality at last follow-up in the IB and DB/CB groups were 0.30% (95% CI: 0.08; 1.17, I2 = 0.0 [p = 1.000]) and 0.48% (95% CI: 0.03; 7.18, I2 = 0.0 [p = 1.000]), respectively. The year of publication (p = 0.044) significantly predicted mortality in the IB group (Fig. 3d).

No direct comparison between the two groups was available for rates of stroke recurrence, dependence, or mortality at last follow-up.

Discussion

Summary of findings

This study represents an accurate systematic review and meta-analysis investigating the role of IB, DB, and CB in pediatric patients with MMD/MMS. Both IB and DB/CB procedures had evidence of efficacy and low rates of complication. A comparative meta-analysis demonstrated a significant benefit in favor of DB/CB in terms of long-term angiographic outcomes, when compared with IB; however, wound complication rates were higher following DB/CB. Other outcomes including perioperative seizures, TIA, stroke, and death were similar between the two groups.

In comparison with the literature

The paucity of studies reporting on DB/CB and widespread available studies investigating IB reflects current patterns of practice favoring IB in the pediatric MMD population. While EDAS and EDAMS were among the originally described techniques for IB, new techniques such as pial synangiosis and multiple burr holes have been added to the surgical armamentarium [38]. Existing evidence is insufficient for there to be consensus regarding the optimal IB technique.

This meta-analysis found low rates of perioperative complications in both DB/CB and IB groups. When compared with IB, CB/DB has been purported to be more technically challenging with a greater risk for postoperative complications [49]. However, many studies have demonstrated the feasibility and safety of DB/CB in pediatric patients with satisfactory outcomes [3, 21, 43, 49]. Factors dissuading the use of DB/CB over IB in the pediatric MMD population, include smaller-caliber recipient and donor vessels, the potential for cross-clamp-induced ischemia, and the risk of poor scalp wound healing. This latter concern was substantiated by the findings of this metanalysis [4, 43]. The lower rates of perioperative adverse events, ranging from wound complications to ischemic events, in our meta-analysis may in general, reflect improved patient selection, anesthetic, and peri-operative care with further knowledge into the management of pediatric MMD/MMS [8]. Regardless of the technique, revascularization should in general be performed in high-volume centers as there is evidence to suggest that caseload correlates with improved care and reduced mortality in pediatric patients with MMD/MMS [68].

In a recent meta-analysis comparing the three bypass techniques in adults, Nguyen et al. [69] found that DB/CB conferred benefits in terms of late stroke recurrence versus IB, with no dissimilarities in terms of perioperative outcomes. Notably, while cerebral hyperperfusion is an undesirable complication of DB in adult patients, this phenomenon is much less frequently observed in pediatric patients and so the conclusions of this study should not constitute a reason to avoid DB in children.

This current metanalysis found evidence of improved angiographic outcomes following DB/CB in comparison with IB; a finding in accordance with previous meta-analyses [70]. Jeon et al. [70] additionally demonstrated a significantly lower risk of future stroke events for DB compared with IB in symptomatic adult patients, although we failed to find evidence of this benefit in our pediatric population.

It has been suggested that patients with various subtypes of MMS undergoing revascularization have poorer outcomes when compared with cases with MMD [5, 7, 19, 20, 59]. Lack of stratification between treatment groups did not allow for a comparison of revascularization strategies between these two pathologies in this current analysis. Furthermore, our meta-regression did not identify the presence of MMS nor its specific phenotypes to significantly affect outcomes; however, this is likely be a function of the limited number of studies reporting them, leading to a Type 2 error. Our meta-regression analysis, however, did identify younger age to be associated with a higher risk of peri-operative stroke and TIA complications. This is consistent with the literature which suggests that younger children with MMD/MMS are thought to be the most severely affected and most challenging to treat [8]. This is likely due to their dynamic clinical course, leading to major strokes on presentation, and poor eventual outcomes [8]. Infants with MMD/MMS have severely compromised cerebrovascular reserve and are particularly vulnerable to anesthetic risks [8].

Clinical implications

As this meta-analysis was not able to directly compare IB and DB/CB for all the stated outcomes, we can at best conclude that both techniques are comparable except for the association of greater rates of angiographic revascularization and wound complication rates in DB/CB. Based on this meta-analysis, it would be prudent to counsel families that although DB/CB is associated of greater rates of angiographic revascularization, this does not necessarily translate into any additional benefit over IB in terms of clinical outcomes such perioperative TIA, perioperative stroke, and long-term stroke recurrence. Indeed, certain studies have suggested a poor correlation between Grades A/B revascularization and future stroke risk [59]. DB/CB allows for immediate augmentation of cerebral blood flow and does not rely on the plasticity and angiogenic potential, unlike IB. In contrast to the immediate flow augmentation by the anastomosis of DB/CB, IB generally relies on the slow neovascularization and recruitment of collaterals over time. In this respect, angiographic success with DB/CB is more reflective of technical anastomosis success. Due to this, the interpretation of angiographic outcomes from IB may be limited if the time to collateral angiogenesis is inadequate, which may explain the findings of our study.

Implication on the direction of future research in MMD/MMS intervention

This systematic review underlines the inconsistency in measurement and reporting within the literature of MMD/MMS. Several included primary studies had not distinguished their outcomes based on the type of bypass, patient population (adult vs pediatric), nor whether or not outcomes were reported in terms of hemispheres or patients. Indeed, previous meta-analyses have also encountered this predicament [10, 11]. This inconsistency in reporting impedes data aggregation and outcome comparison across studies, hindering progress in MMD/MMS management. Conducting a randomized controlled trial in pediatric patients with a rare progressive disease such as MMD/MMS is near impossible due to ethical reasons [1, 2], which highlights the urgency and need for greater standardization in reporting. Consistent reporting in MMD/MMS can be facilitated by an agreed minimum set of indicators to be reported. With a unified standard of data reporting, this will enable valid evidence syntheses and ultimately implementation of management recommendations.

Limitations

Limitations of this meta-analysis include the retrospective and observational nature of included studies. Our study has also highlighted the limited number of studies directly comparing DB/CB and IB for MMD/MMS. This could explain the finding of non-significance in the various outcomes. Additionally, apart from perioperative events, there were no standard time frame with different lengths of clinical follow-up in each study. Furthermore, several outcomes reported in this study have a large encompassing confidence interval, which may be explained by the modest sample size and large heterogeneity between studies. As such, we advise to interpret these outcomes with great caution as the estimates were unlikely to be reliable. Only studies published in English were included; therefore, selection bias may exist because MMD has greater incidence rates among Asian populations. Based on the information from the included studies, our current meta-analysis could not assess whether or not the translation of subjective angiographic assessments across grading scales were accurate in the pediatric cohort. A possible relationship may be uncovered in future with more granular detail. Validation can be achieved by establishing a prospective data registry collected from multiple international centers which can inform future individual participant data meta-analysis in real-world settings. Our meta-analysis included a diverse range of patients of various ethnic diversity, enhancing its external validity. The large number of studies enabled us to perform a meta-regression to explore possible confounders. However, we cannot exclude the possibility that the conclusions drawn in our study may have been affected by residual confounders. Confounders that we did not control for in our analyses include surgeon experience although we controlled for the year of publication given that the surgical and peri-operative management of these patients has generally improved over time due to greater accrued understanding of the condition with time. Most importantly, this meta-analysis is the most reliable and transparent to date as we excluded repeated patient populations from the same institutions within overlapping time intervals.

Conclusions

IB, DB/CB techniques have both been demonstrated to be effective and safe revascularization options for pediatric MMD/MMS. A paucity of cohort studies has a limit direct comparison between these interventions. Available low-quality GRADE evidence suggests that DB/CB is associated with better long-term revascularization outcomes when compared with IB alone, although this did not translate to better long-term stroke outcomes.

Supplementary Information

Below is the link to the electronic supplementary material.

Acknowledgements

A special thank you to Kenneth Kek Wee Lee (Papa), Lena Lim (Mama), and Chio Tee Koh (Ahma) back home for their unwavering support, without which, I (Keng Siang Lee) would not be able to achieve my educational goals. Love truly overcomes all obstacles (different time zones and distance). I love you all!

Author contribution

All authors listed have made substantial, direct, and intellectual contribution to the work and approved it for publications. Keng Siang Lee: conceptualization, methodology, formal analysis and investigation, writing—original draft preparation, writing—review and editing, visualization, funding acquisition. John J. Y. Zhang: conceptualization, methodology, formal analysis and investigation, writing—review and editing, visualization. Sanjay Bhate: writing—review and editing, supervision. Vijeya Ganesan: writing—review and editing, supervision. Dominic Thompson: conceptualization, writing—review and editing, supervision. Greg James: conceptualization, writing—review and editing, supervision. Adikarige Haritha Dulanka Silva: conceptualization, writing—review and editing, supervision.

Availability of data and material

Not applicable.

Code availability

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Consent for publication

Not applicable.

Conflict of interest

The authors declare that they have no conflict of interest.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Keng Siang Lee and John J. Y. Zhang share co-first authorship.

References

  • 1.Scott RM, Smith ER. Moyamoya disease and moyamoya syndrome. N Engl J Med. 2009;360(12):1226–1237. doi: 10.1056/NEJMra0804622. [DOI] [PubMed] [Google Scholar]
  • 2.Scott RM et al (2004) Long-term outcome in children with moyamoya syndrome after cranial revascularization by pial synangiosis. J Neurosurg 100(2 Suppl Pediatrics):p. 142–9 [DOI] [PubMed]
  • 3.Matsushima T et al (1998) Multiple combined indirect procedure for the surgical treatment of children with moyamoya disease. A comparison with single indirect anastomosis and direct anastomosis. Neurosurg Focus 5(5):p. e4 [DOI] [PubMed]
  • 4.Morshed RA, et al. Clinical outcomes after revascularization for pediatric moyamoya disease and syndrome: a single-center series. J Clin Neurosci. 2020;79:137–143. doi: 10.1016/j.jocn.2020.07.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Koss M, et al. Moyamoya syndrome associated with neurofibromatosis Type 1: perioperative and long-term outcome after surgical revascularization. J Neurosurg Pediatr. 2013;11(4):417–425. doi: 10.3171/2012.12.PEDS12281. [DOI] [PubMed] [Google Scholar]
  • 6.Karsten MB, Smith ER, Scott RM (2021) Late morbidity and mortality following revascularization surgery for moyamoya disease in the pediatric population. J Neurosurg Pediatr p. 1–6 [DOI] [PubMed]
  • 7.Smith ER, et al. Pial synangiosis in patients with moyamoya syndrome and sickle cell anemia: perioperative management and surgical outcome. Neurosurg Focus. 2009;26(4):E10. doi: 10.3171/2009.01.FOCUS08307. [DOI] [PubMed] [Google Scholar]
  • 8.Jackson EM, et al. Pial synangiosis in patients with moyamoya younger than 2 years of age. J Neurosurg Pediatr. 2014;13(4):420–425. doi: 10.3171/2014.1.PEDS13251. [DOI] [PubMed] [Google Scholar]
  • 9.Montaser A et al (2021) Long-term clinical and radiographic outcomes after pial pericranial dural revascularization: a hybrid surgical technique for treatment of anterior cerebral territory ischemia in pediatric moyamoya disease. J Neurosurg Pediatr p. 1–9 [DOI] [PubMed]
  • 10.Ravindran K, Wellons JC, Dewan MC. Surgical outcomes for pediatric moyamoya: a systematic review and meta-analysis. J Neurosurg Pediatr. 2019;24(6):663–672. doi: 10.3171/2019.6.PEDS19241. [DOI] [PubMed] [Google Scholar]
  • 11.Macyszyn L, et al. Direct versus indirect revascularization procedures for moyamoya disease: a comparative effectiveness study. J Neurosurg. 2017;126(5):1523–1529. doi: 10.3171/2015.8.JNS15504. [DOI] [PubMed] [Google Scholar]
  • 12.Lunny C, et al. Managing overlap of primary study results across systematic reviews: practical considerations for authors of overviews of reviews. BMC Med Res Methodol. 2021;21(1):140. doi: 10.1186/s12874-021-01269-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Czabanka M, et al. Characterization of direct and indirect cerebral revascularization for the treatment of European patients with moyamoya disease. Cerebrovasc Dis. 2011;32(4):361–369. doi: 10.1159/000330351. [DOI] [PubMed] [Google Scholar]
  • 15.Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Measur. 1960;20(1):37–47. doi: 10.1177/001316446002000104. [DOI] [Google Scholar]
  • 16.Lee KS, et al. Tenets for the proper conduct and use of meta-analyses: a practical guide for neurosurgeons. World Neurosurg. 2022;161:291–302.e1. doi: 10.1016/j.wneu.2021.09.034. [DOI] [PubMed] [Google Scholar]
  • 17.Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5(1):13. doi: 10.1186/1471-2288-5-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Wan X, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14(1):135. doi: 10.1186/1471-2288-14-135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Kennedy BC, et al. Pial synangiosis for moyamoya syndrome in children with sickle cell anemia: a comprehensive review of reported cases. Neurosurg Focus. 2014;36(1):E12. doi: 10.3171/2013.10.FOCUS13405. [DOI] [PubMed] [Google Scholar]
  • 20.See AP, et al. Down syndrome and moyamoya: clinical presentation and surgical management. J Neurosurg Pediatr. 2015;16(1):58–63. doi: 10.3171/2014.12.PEDS14563. [DOI] [PubMed] [Google Scholar]
  • 21.Zhao M, et al. Adolescents with moyamoya disease: clinical features, surgical treatment and long-term outcomes. Acta Neurochir (Wien) 2017;159(11):2071–2080. doi: 10.1007/s00701-017-3286-x. [DOI] [PubMed] [Google Scholar]
  • 22.Zhao Y, et al. Comparison of long-term effect between direct and indirect bypass for pediatric ischemic-type moyamoya disease: a propensity score-matched study. Front Neurol. 2019;10:795. doi: 10.3389/fneur.2019.00795. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Zheng J, et al. Clinical features, surgical treatment, and long-term outcome of a multicenter cohort of pediatric moyamoya. Front Neurol. 2019;10:14. doi: 10.3389/fneur.2019.00014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Ge P, et al. Clinical features, surgical treatment, and long-term outcome in children with hemorrhagic moyamoya disease. J Stroke Cerebrovasc Dis. 2018;27(6):1517–1523. doi: 10.1016/j.jstrokecerebrovasdis.2017.12.047. [DOI] [PubMed] [Google Scholar]
  • 25.Wang C, et al. Encephaloduroarteriosynangiosis for pediatric moyamoya disease: a single-center experience with 67 cases in China. J Child Neurol. 2018;33(14):901–908. doi: 10.1177/0883073818798515. [DOI] [PubMed] [Google Scholar]
  • 26.Ahn ES, et al. Chorea in the clinical presentation of moyamoya disease: results of surgical revascularization and a proposed clinicopathological correlation. J Neurosurg Pediatr. 2013;11(3):313–319. doi: 10.3171/2012.11.PEDS12199. [DOI] [PubMed] [Google Scholar]
  • 27.Gaillard J, et al. Incidence, clinical features, and treatment of familial moyamoya in pediatric patients: a single-institution series. J Neurosurg Pediatr. 2017;19(5):553–559. doi: 10.3171/2016.12.PEDS16468. [DOI] [PubMed] [Google Scholar]
  • 28.Riordan CP et al (2019) Results of more than 20 years of follow-up in pediatric patients with moyamoya disease undergoing pial synangiosis. J Neurosurg Pediatr p. 1–7 [DOI] [PubMed]
  • 29.Jea A, et al. Moyamoya syndrome associated with Down syndrome: outcome after surgical revascularization. Pediatrics. 2005;116(5):e694–701. doi: 10.1542/peds.2005-0568. [DOI] [PubMed] [Google Scholar]
  • 30.Robertson RL, et al. Angiographic changes after pial synangiosis in childhood moyamoya disease. AJNR Am J Neuroradiol. 1997;18(5):837–845. [PMC free article] [PubMed] [Google Scholar]
  • 31.Kim SK, et al. Pediatric moyamoya disease: an analysis of 410 consecutive cases. Ann Neurol. 2010;68(1):92–101. doi: 10.1002/ana.21981. [DOI] [PubMed] [Google Scholar]
  • 32.Choi JW, et al. Postoperative symptomatic cerebral infarction in pediatric moyamoya disease: risk factors and clinical outcome. World Neurosurg. 2020;136:e158–e164. doi: 10.1016/j.wneu.2019.12.072. [DOI] [PubMed] [Google Scholar]
  • 33.Phi JH, et al. Long-term social outcome in children with moyamoya disease who have reached adulthood. J Neurosurg Pediatr. 2011;8(3):303–309. doi: 10.3171/2011.6.PEDS10578. [DOI] [PubMed] [Google Scholar]
  • 34.Kim CY, et al. Encephaloduroarteriosynangiosis with bifrontal encephalogaleo(periosteal)synangiosis in the pediatric moyamoya disease: the surgical technique and its outcomes. Childs Nerv Syst. 2003;19(5–6):316–324. doi: 10.1007/s00381-003-0742-0. [DOI] [PubMed] [Google Scholar]
  • 35.Alamri A, et al. Encephaloduroateriosynangiosis (EDAS) in the management of Moyamoya syndrome in children with sickle cell disease. Br J Neurosurg. 2019;33(2):161–164. doi: 10.1080/02688697.2017.1339227. [DOI] [PubMed] [Google Scholar]
  • 36.Araki Y, et al. Risk factors for cerebral infarction early after revascularization in children younger than 5 years with moyamoya disease. World Neurosurg. 2022;160:e220–e226. doi: 10.1016/j.wneu.2021.12.115. [DOI] [PubMed] [Google Scholar]
  • 37.Bao XY, et al. Clinical features, surgical treatment, and long-term outcome in pediatric patients with moyamoya disease in China. Cerebrovasc Dis. 2015;39(2):75–81. doi: 10.1159/000369524. [DOI] [PubMed] [Google Scholar]
  • 38.Blauwblomme T, et al. Long-term outcome after multiple burr hole surgery in children with moyamoya angiopathy: a single-center experience in 108 hemispheres. Neurosurgery. 2017;80(6):950–956. doi: 10.1093/neuros/nyw161. [DOI] [PubMed] [Google Scholar]
  • 39.Chen C, et al. Surgical revascularization for children with moyamoya disease: a new modification to the pial synangiosis. World Neurosurg. 2018;110:e203–e211. doi: 10.1016/j.wneu.2017.10.137. [DOI] [PubMed] [Google Scholar]
  • 40.Czabanka M, et al. Age-dependent revascularization patterns in the treatment of moyamoya disease in a European patient population. Neurosurg Focus. 2009;26(4):E9. doi: 10.3171/2009.1.FOCUS08298. [DOI] [PubMed] [Google Scholar]
  • 41.Darwish B, Besser M. Long term outcome in children with Moyamoya disease: experience with 16 patients. J Clin Neurosci. 2005;12(8):873–877. doi: 10.1016/j.jocn.2004.11.008. [DOI] [PubMed] [Google Scholar]
  • 42.Oliveira RS, et al. Effect of multiple cranial burr hole surgery on prevention of recurrent ischemic attacks in children with moyamoya disease. Neuropediatrics. 2009;40(6):260–264. doi: 10.1055/s-0030-1249069. [DOI] [PubMed] [Google Scholar]
  • 43.Deng X, et al. Risk factors for postoperative ischemic complications in pediatric moyamoya disease. BMC Neurol. 2021;21(1):229. doi: 10.1186/s12883-021-02283-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Funaki T et al (2014) Incidence of late cerebrovascular events after direct bypass among children with moyamoya disease: a descriptive longitudinal study at a single center. Acta Neurochir (Wien) 156(3):p. 551–9; discussion 559 [DOI] [PubMed]
  • 45.Furtado SV, et al. Surgical outcome of encephaloduroarteriomyosynangiosis for moyamoya disease. Neurol India. 2021;69(5):1259–1264. doi: 10.4103/0028-3886.329538. [DOI] [PubMed] [Google Scholar]
  • 46.Gadgil N, et al. Indirect revascularization with the dural inversion technique for pediatric moyamoya disease: 20-year experience. J Neurosurg Pediatr. 2018;22(5):541–549. doi: 10.3171/2018.5.PEDS18163. [DOI] [PubMed] [Google Scholar]
  • 47.Goren O, et al. Encephaloduroarteriosynangiosis with dural inversion for moyamoya disease in a pediatric and adult population-a single-center 20-year experience. World Neurosurg. 2021;149:e16–e21. doi: 10.1016/j.wneu.2021.02.102. [DOI] [PubMed] [Google Scholar]
  • 48.Griessenauer CJ, et al. Encephaloduroarteriosynangiosis and encephalomyoarteriosynangiosis for treatment of moyamoya syndrome in pediatric patients with sickle cell disease. J Neurosurg Pediatr. 2015;16(1):64–73. doi: 10.3171/2014.12.PEDS14522. [DOI] [PubMed] [Google Scholar]
  • 49.Guzman R, et al. Clinical outcome after 450 revascularization procedures for moyamoya disease: clinical article. J Neurosurg. 2009;111(5):927–935. doi: 10.3171/2009.4.JNS081649. [DOI] [PubMed] [Google Scholar]
  • 50.Ha EJ, et al. Long-term outcomes of indirect bypass for 629 children with moyamoya disease: longitudinal and cross-sectional analysis. Stroke. 2019;50(11):3177–3183. doi: 10.1161/STROKEAHA.119.025609. [DOI] [PubMed] [Google Scholar]
  • 51.Hall EM, et al. Reduction in overt and silent stroke recurrence rate following cerebral revascularization surgery in children with sickle cell disease and severe cerebral vasculopathy. Pediatr Blood Cancer. 2016;63(8):1431–1437. doi: 10.1002/pbc.26022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Ishikawa T, et al. Effects of surgical revascularization on outcome of patients with pediatric moyamoya disease. Stroke. 1997;28(6):1170–1173. doi: 10.1161/01.STR.28.6.1170. [DOI] [PubMed] [Google Scholar]
  • 53.Isono M, et al. Long-term outcomes of pediatric moyamoya disease treated by encephalo-duro-arterio-synangiosis. Pediatr Neurosurg. 2002;36(1):14–21. doi: 10.1159/000048343. [DOI] [PubMed] [Google Scholar]
  • 54.Karasawa J, et al. Long-term follow-up study after extracranial-intracranial bypass surgery for anterior circulation ischemia in childhood moyamoya disease. J Neurosurg. 1992;77(1):84–89. doi: 10.3171/jns.1992.77.1.0084. [DOI] [PubMed] [Google Scholar]
  • 55.Kim DS, et al. Surgical results in pediatric moyamoya disease: angiographic revascularization and the clinical results. Clin Neurol Neurosurg. 2007;109(2):125–131. doi: 10.1016/j.clineuro.2006.06.004. [DOI] [PubMed] [Google Scholar]
  • 56.King JA, et al. Relative contributions of the middle meningeal artery and superficial temporal artery in revascularization surgery for moyamoya syndrome in children: the results of superselective angiography. J Neurosurg Pediatr. 2010;5(2):184–189. doi: 10.3171/2009.9.PEDS0932. [DOI] [PubMed] [Google Scholar]
  • 57.Kuroda S et al (2010) Novel bypass surgery for moyamoya disease using pericranial flap: its impacts on cerebral hemodynamics and long-term outcome. Neurosurgery 66(6):1093–101; discussion 1101 [DOI] [PubMed]
  • 58.Mirone G, et al. Multiple burr-hole surgery for the treatment of moyamoya disease and quasi-moyamoya disease in children: preliminary surgical and imaging results. World Neurosurg. 2019;127:e843–e855. doi: 10.1016/j.wneu.2019.03.282. [DOI] [PubMed] [Google Scholar]
  • 59.Ng J, et al. Surgical revascularisation for childhood moyamoya. Childs Nerv Syst. 2012;28(7):1041–1048. doi: 10.1007/s00381-012-1743-7. [DOI] [PubMed] [Google Scholar]
  • 60.Ogiwara H, Morota N. Bifrontal encephalogaleosynangiosis for children with moyamoya disease. J Neurosurg Pediatr. 2012;10(3):246–251. doi: 10.3171/2012.6.PEDS11483. [DOI] [PubMed] [Google Scholar]
  • 61.Ong JA, et al. Revascularisation surgery for paediatric moyamoya disease: The Singapore experience. J Clin Neurosci. 2020;82(Pt B):207–213. doi: 10.1016/j.jocn.2020.11.008. [DOI] [PubMed] [Google Scholar]
  • 62.Rashad S, et al. Long-term follow-up of pediatric moyamoya disease treated by combined direct-indirect revascularization surgery: single institute experience with surgical and perioperative management. Neurosurg Rev. 2016;39(4):615–623. doi: 10.1007/s10143-016-0734-7. [DOI] [PubMed] [Google Scholar]
  • 63.Sadashiva N, et al. Moyamoya disease: experience with direct and indirect revascularization in 70 patients from a nonendemic region. Neurol India. 2016;64(Suppl):S78–86. doi: 10.4103/0028-3886.178046. [DOI] [PubMed] [Google Scholar]
  • 64.Sakamoto H, et al. Direct extracranial-intracranial bypass for children with moyamoya disease. Clin Neurol Neurosurg. 1997;99(Suppl 2):S128–S133. doi: 10.1016/S0303-8467(97)00071-1. [DOI] [PubMed] [Google Scholar]
  • 65.Shen W, et al. Enlarged encephalo-duro-myo-synangiosis treatment for moyamoya disease in young children. World Neurosurg. 2017;106:9–16. doi: 10.1016/j.wneu.2017.06.088. [DOI] [PubMed] [Google Scholar]
  • 66.Winstead M, et al. Encephaloduroarteriosynangiosis (EDAS) in young patients with cerebrovascular complications of sickle cell disease: single-institution experience. Pediatr Hematol Oncol. 2017;34(2):100–106. doi: 10.1080/08880018.2017.1313917. [DOI] [PubMed] [Google Scholar]
  • 67.Yang W, et al. Effectiveness of surgical revascularization for stroke prevention in pediatric patients with sickle cell disease and moyamoya syndrome. J Neurosurg Pediatr. 2017;20(3):232–238. doi: 10.3171/2017.1.PEDS16576. [DOI] [PubMed] [Google Scholar]
  • 68.Titsworth WL, Scott RM, Smith ER. National analysis of 2454 pediatric moyamoya admissions and the effect of hospital volume on outcomes. Stroke. 2016;47(5):1303–1311. doi: 10.1161/STROKEAHA.115.012168. [DOI] [PubMed] [Google Scholar]
  • 69.Nguyen VN et al (2022) Direct, indirect, and combined extracranial-to-intracranial bypass for adult moyamoya disease: an updated systematic review and meta-analysis. Stroke p. 101161STROKEAHA122039584 [DOI] [PubMed]
  • 70.Jeon JP, et al. Meta-analysis of the surgical outcomes of symptomatic moyamoya disease in adults. J Neurosurg. 2018;128(3):793–799. doi: 10.3171/2016.11.JNS161688. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Data Availability Statement

Not applicable.

Not applicable.


Articles from Child's Nervous System are provided here courtesy of Springer

RESOURCES